Literature DB >> 26138469

Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Aditya J Desai1, Maoqing Dong1, Kaleeckal G Harikumar1, Laurence J Miller2.   

Abstract

Dysfunction of the type 1 cholecystokinin (CCK) receptor (CCK1R) as a result of increased gallbladder muscularis membrane cholesterol has been implicated in the pathogenesis of cholesterol gallstones. Administration of ursodeoxycholic acid, which is structurally related to cholesterol, has been shown to have beneficial effects on gallstone formation. Our aims were to explore the possible direct effects and mechanism of action of bile acids on CCK receptor function. We studied the effects of structurally related hydrophobic chenodeoxycholic acid and hydrophilic ursodeoxycholic acid in vitro on CCK receptor function in the setting of normal and elevated membrane cholesterol. We also examined their effects on a cholesterol-insensitive CCK1R mutant (Y140A) disrupting a key site of cholesterol action. The results show that, similar to the impact of cholesterol on CCK receptors, bile acid effects were limited to CCK1R, with no effects on CCK2R. Chenodeoxycholic acid had a negative impact on CCK1R function, while ursodeoxycholic acid had no effect on CCK1R function in normal membranes but was protective against the negative impact of elevated cholesterol on this receptor. The cholesterol-insensitive CCK1R mutant Y140A was resistant to effects of both bile acids. These data suggest that bile acids compete with the action of cholesterol on CCK1R, probably by interacting at the same site, although the conformational impact of each bile acid appears to be different, with ursodeoxycholic acid capable of correcting the abnormal conformation of CCK1R in a high-cholesterol environment. This mechanism may contribute to the beneficial effect of ursodeoxycholic acid in reducing cholesterol gallstone formation.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  bile acids; cholecystokinin; cholesterol; gallstone disease

Mesh:

Substances:

Year:  2015        PMID: 26138469      PMCID: PMC4556949          DOI: 10.1152/ajpgi.00173.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  52 in total

1.  Altered signal pathway in granulocytes from patients with hypercholesterolemia.

Authors:  G Paragh; E Kovács; I Seres; T Keresztes; Z Balogh; J Szabó; F Teichmann; G Fóris
Journal:  J Lipid Res       Date:  1999-09       Impact factor: 5.922

2.  Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study.

Authors:  M Cofán; V Escurriol; A L García-Otín; C Moreno-Iribas; N Larrañaga; M J Sánchez; M J Tormo; M L Redondo; C A González; D Corella; M Pocoví; F Civeira; E Ros
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-05-31       Impact factor: 4.222

3.  Enhanced gallbladder absorption during gallstone formation: the roles of cholesterol saturated bile and gallbladder stasis.

Authors:  J J Roslyn; J Doty; H A Pitt; R L Conter; L Den Besten
Journal:  Am J Med Sci       Date:  1986-08       Impact factor: 2.378

4.  Isolation of sterol-resistant Chinese hamster ovary cells with genetic deficiencies in both Insig-1 and Insig-2.

Authors:  Peter C W Lee; Navdar Sever; Russell A Debose-Boyd
Journal:  J Biol Chem       Date:  2005-05-02       Impact factor: 5.157

5.  Excess membrane cholesterol alters human gallbladder muscle contractility and membrane fluidity.

Authors:  Q Chen; J Amaral; P Biancani; J Behar
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

6.  Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans.

Authors:  C Kreiss; W Schwizer; J Borovicka; J B Jansen; C Bouloux; R Pignol; A Bischof Delaloye; M Fried
Journal:  Regul Pept       Date:  1998-06-30

7.  2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.

Authors:  Richard Berger; Cheng Zhu; Alexa R Hansen; Bart Harper; Zhesheng Chen; Tom G Holt; James Hubert; Susan J Lee; Jie Pan; Su Qian; Marc L Reitman; Alison M Strack; Drew T Weingarth; Michael Wolff; Douglas J Macneil; Ann E Weber; Scott D Edmondson
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

8.  The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity.

Authors:  G Nardone; I A Ferber; L J Miller
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

9.  Current views on genetics and epigenetics of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Cholesterol       Date:  2013-04-14

10.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555

View more
  6 in total

Review 1.  Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

2.  Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.

Authors:  Aditya J Desai; Maoqing Dong; Laurence J Miller
Journal:  Clin Nutr       Date:  2016-03-15       Impact factor: 7.324

Review 3.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

4.  Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.

Authors:  Aditya J Desai; Maoqing Dong; Blake T Langlais; Amylou C Dueck; Laurence J Miller
Journal:  Am J Clin Nutr       Date:  2017-06-07       Impact factor: 7.045

5.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

Review 6.  Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics.

Authors:  Laurence J Miller; Kaleeckal G Harikumar; Denise Wootten; Patrick M Sexton
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.